Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have patented cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Who is Merck Sharp & Dohme Corp.? Merck Sharp & Dohme Corp. has an estimated net worth of $1.18 Billion. This is based on reported shares across multiple companies, which include OPGEN INC ...

America's pharmaceutical founding fathers Meanwhile ... whilst “American” Merck (now Merck & Co. in the US or Merck Sharp & Dohme (MSD) elsewhere) was compulsorily split off from its Germany ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against the other best major stocks ...

In the last few weeks, the PTAB has granted institution of eight IPRs filed by Merck on Johns Hopkins patents directed to methods of ...

Merck, known as Merck, Sharp and Dohme (MSD) outside the US, markets several diabetes drugs, such as Januvia (sitagliptin), and the recently-approved Steglatro (ertugliflozin) as part of a ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Key Takeaways For Merck & Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE, EBITDA ...

Merck's recent decline is due to reduced profit ... It is also often the case that pharmaceutical companies and related healthcare equities become volatile and sustain temporary declines prior ...